Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (AZNCF)
OTHER OTC:AZNCF
AZNCF Stock Chart & Stats
$191.12
$0.78(0.59%)
At close: 4:00 PM EST
$191.12
$0.78(0.59%)
Day’s Range― - ―
52-Week Range$122.26 - $192.90
Previous CloseN/A
Volume3.14K
Average Volume (3M)3.76K
Market Cap
$291.02B
Enterprise Value$176.61B
Total Cash (Recent Filing)$8.18B
Total Debt (Recent Filing)$32.66B
Price to Earnings (P/E)31.1
Beta0.06
Next Earnings
Feb 10, 2026EPS Estimate
2.12Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)2.38
Shares Outstanding1,550,908,000
10 Day Avg. Volume2,202
30 Day Avg. Volume3,757
Financial Highlights & Ratios
PEG Ratio2.17
Price to Book (P/B)4.98
Price to Sales (P/S)3.83
P/FCF Ratio27.90
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit4.01
Enterprise Value/Ebitda8.94
Forecast
1Y Price Target
$195.75Price Target Upside2.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CAR-T And T-cell Engager ProgramsAnalyst highlights CAR-T and T-cell engager approaches with short manufacturing times, outpatient feasibility, favorable safety, and early efficacy signals that could enable regulatory filings and wider market access.
COPD Therapy DifferentiationAnalyst notes tozorakimab's unique mechanism targeting epithelial remodeling and mucus hypersecretion could distinguish the COPD program from competitors and support stronger uptake.
Pipeline And Valuation UpsideAnalyst views valuation as attractive and expects upside from a broad pipeline, with several phase three non-oncology assets and key oncology readouts that could drive a rerating and higher earnings expectations.
Bears Say
Generic Competition RiskAnalyst raises concern that earlier generic competition to Farxiga in Europe could compress sales and negatively affect earnings.
Product Erosion And Regional ShortfallsAnalyst notes continued erosion of Brilinta in the US due to generics and a Pulmicort sales shortfall in China, which could pressure near-term revenue momentum.
Trial Timing UncertaintyAnalyst warns that slower event rates and study delays introduce uncertainty around the timing of key readouts, reducing visibility for development programs.
AstraZeneca News
AZNCF FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest stock price was $122.26 and its highest was $192.90 in the past 12 months.
What is AstraZeneca PLC’s market cap?
AstraZeneca PLC’s market cap is $291.02B.
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Feb 10, 2026 which is in 24 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Nov 06, 2025. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $2.293 by $0.087.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Semiannually dividend of $1.025 which represents an annual dividend yield of 1.72%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is 2.12.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,908,000 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of $2.38 in its last earnings report, beating expectations of $2.293. Following the earnings report the stock price went up 5.721%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in AZNCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$195.75 (2.42% Upside)
$195.75 (2.42% Upside)
Insider Transactions
Sold Shares
Worth £1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.45%
12-Months-Change
Fundamentals
Return on Equity
20.09%
Trailing 12-Months
Asset Growth
-0.61%
Trailing 12-Months
Company Description
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZNCF Stock 12 Month Forecast
Average Price Target
$195.75
▲(2.42% Upside)
Technical Analysis
ConvaTec
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Ownership Overview
0.02% Insiders
12.83% Mutual Funds
0.02% Other Institutional Investors
76.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---